Used in targeted cancer therapies, particularly for colorectal and gastric cancers expressing the GPA33 antigen. It serves as a reference antibody in immunoassays to evaluate binding affinity and specificity of experimental anti-GPA33 antibodies. Employed in antibody-drug conjugate (ADC) development to deliver cytotoxic agents selectively to tumor cells. Also utilized in imaging studies to track tumor localization and monitor treatment response in preclinical models. Supports research in immunotherapy by helping characterize immune cell engagement and tumor antigen expression.